OMER

+ Watchlist + Portfolio

Omeros Corp.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $18.39
52-Week Range: $3.94 – $18.89
Market Cap: $1.35B
P/E (TTM): 11.16
EPS (TTM): 1.67
Dividend Yield: —

Advanced Metrics

Price/Book: —
PEG Ratio: 0.81
Return on Equity: —
Return on Assets: -18.68%
Gross Margin: 38.34%
Operating Margin: 0.26%
Profit Margin: 324.88%
Current Ratio: 1.95
Debt/Equity: —
Total Debt: $296.87M
Free Cash Flow: $183.31M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $1.51B

OMER Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$112.72M	$114.87M	$119.52M	$81.30M
Selling, General & Admin	$50.67M	$49.66M	$47.43M	$41.50M
Operating Expenses	$163.39M	$164.53M	$166.95M	$122.80M
Operating Income	-$163.39M	-$164.53M	-$166.95M	-$122.80M
EBITDA	-$158.38M	-$143.16M	-$154.70M	-$121.83M
Pretax Income	-$182.03M	-$174.92M	-$180.32M	-$2.80M
Income Tax	$0.00	$0.00	$2.31M	$2.01M
Net Income	$47.42M	-$117.81M	-$156.81M	-$3.35M
Diluted EPS	0.76	-1.88	-2.70	-0.05
Diluted Shares	62.74M	62.74M	58.17M	63.51M

OMER Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$11.01M	$7.11M	$3.40M	$9.66M
Receivables	$242.02M	$37.47M	$36.82M	$36.27M
Current Assets	$443.24M	$217.90M	$134.12M	$215.67M
Total Assets	$590.97M	$378.27M	$277.08M	$325.63M
Current Liabilities	$136.38M	$53.32M	$79.53M	$78.06M
Long-Term Debt	$220.91M	$213.16M	$166.58M	$208.53M
Total Debt	$342.02M	$236.46M	$207.02M	$239.14M
Total Liabilities	$505.29M	$403.25M	$459.69M	$446.86M
Retained Earnings	-$635.72M	-$753.53M	-$910.35M	-$913.70M
Shareholders' Equity	$85.68M	-$24.98M	-$182.61M	-$121.23M
Working Capital	$306.85M	$164.58M	$54.59M	$137.60M
Net Debt	$304.28M	$206.05M	$184.18M	$215.94M

OMER Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$86.48M	$74.73M	-$148.80M	-$116.09M
Capital Expenditure	-$113.00K	-$426.00K	-$165.00K	-$65.00K
Free Cash Flow	-$86.60M	$74.30M	-$148.97M	-$116.16M
Depreciation & Amortisation	$952.00K	$920.00K	$950.00K	$964.00K
Stock-Based Compensation	$14.07M	$11.65M	$10.49M	$8.19M
Investing Cash Flow	-$127.56M	$27.45M	$82.22M	$164.52M
Financing Cash Flow	$124.25M	-$106.08M	$62.88M	-$42.17M
Share Repurchases	$0.00	-$4.65M	-$11.85M	$0.00
Net Change in Cash	-$89.80M	-$3.90M	-$3.71M	$6.26M

OMER Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$9.89M
Cost of Revenue	$0.00	—	—	—	$587.00K
Gross Profit	$0.00	—	—	—	$9.31M
Research & Development	$23.85M	$22.01M	$15.99M	$19.45M	$13.36M
Selling, General & Admin	$11.12M	$10.35M	$10.40M	$9.63M	$13.37M
Operating Expenses	$34.97M	$32.35M	$26.39M	$29.08M	$26.73M
Operating Income	-$34.97M	-$32.35M	-$26.39M	-$29.08M	-$17.42M
EBITDA	-$33.62M	-$25.67M	-$26.15M	-$28.85M	$57.44M
Pretax Income	-$37.56M	-$25.89M	-$21.24M	$81.90M	$51.31M
Income Tax	$0.00	—	—	—	$57.00K
Net Income	-$33.46M	-$25.42M	-$30.92M	$86.45M	$56.06M
Diluted EPS	-0.58	-0.43	-0.47	0.98	0.62
Diluted Shares	58.06M	58.59M	66.26M	88.48M	90.12M

OMER Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$4.26M	$1.90M	$2.40M	$9.66M	$1.91M
Receivables	$36.30M	$34.50M	$31.96M	$36.27M	$37.51M
Inventory	—	—	—	—	$183.00K
Current Assets	$96.18M	$69.65M	$71.81M	$215.67M	$180.35M
Total Assets	$235.16M	$200.57M	$185.71M	$325.63M	$286.17M
Current Liabilities	$83.22M	$85.50M	$80.76M	$78.06M	$59.44M
Long-Term Debt	$158.96M	$150.79M	$159.56M	$208.53M	$136.84M
Total Debt	$203.88M	$184.33M	$191.61M	$239.14M	$148.85M
Total Liabilities	$448.71M	$429.25M	$406.18M	$446.86M	$349.51M
Retained Earnings	-$943.80M	-$969.23M	-$1.00B	-$913.70M	-$857.63M
Shareholders' Equity	-$213.55M	-$228.69M	-$220.48M	-$121.23M	-$63.33M
Working Capital	$12.96M	-$15.86M	-$8.95M	$137.60M	$120.91M
Net Debt	$181.63M	$165.90M	$174.20M	$215.94M	$134.93M

OMER Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$35.84M	-$21.94M	-$18.47M	-$39.84M	-$14.51M
Capital Expenditure	-$41.00K	-$13.00K	-$11.00K	—	—
Free Cash Flow	-$35.88M	-$21.95M	-$18.48M	-$39.84M	-$14.51M
Depreciation & Amortisation	$289.00K	$200.00K	$240.00K	$235.00K	$239.00K
Stock-Based Compensation	$2.45M	$2.06M	$1.94M	$1.73M	$1.89M
Investing Cash Flow	$38.54M	$21.30M	-$6.86M	$111.55M	$28.73M
Financing Cash Flow	-$1.84M	-$1.72M	$25.82M	-$64.44M	-$21.98M
Share Repurchases	$0.00	$0.00	$0.00	$0.00	-$4.15M
Net Change in Cash	$861.00K	-$2.36M	$491.00K	$7.26M	-$7.75M

Market Snapshot

About

Omeros Corporation is a biopharmaceutical company focused on therapies targeting complement-mediated diseases and central nervous system disorders. The company's products and pipeline include treatments for surgical bleeding, renal disease, and neurological conditions. Omeros markets Omidria, an ophthalmic drug used during cataract surgery.